StockData
BioCryst Pharmaceuticals Inc logo

BioCryst Pharmaceuticals Inc (BCRX) stock

BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$7.50+0.05 (+0.67%)

Close on Nov 17, 2026Market cap $1.92BP/E –Yield –

BioCryst Pharmaceuticals total assets

Total assets on the balance sheet at the end of each period.

BioCryst Pharmaceuticals's total assets was $557.85M at Jun 30, 2026. For fiscal 2025 it was $514.16M, up 4.8% from the year before. Over ten years it grew 15.4% a year on average. The highest annual figure on record is $588.15M in fiscal 2021.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$514.16M+4.8%
FY2024Dec 31, 2024$490.42M-5.1%
FY2023Dec 31, 2023$516.96M-6.0%
FY2022Dec 31, 2022$550.00M-6.5%
FY2021Dec 31, 2021$588.15M+75.7%
FY2020Dec 31, 2020$334.72M+91.0%
FY2019Dec 31, 2019$175.28M+19.4%
FY2018Dec 31, 2018$146.84M-17.6%
FY2017Dec 31, 2017$178.26M+98.4%
FY2016Dec 31, 2016$89.85M-26.6%
FY2015Dec 31, 2015$122.36M-10.6%
FY2014Dec 31, 2014$136.87M+180.1%
FY2013Dec 31, 2013$48.87M-14.9%
FY2012Dec 31, 2012$57.44M-30.1%
FY2011Dec 31, 2011$82.21M-24.9%
FY2010Dec 31, 2010$109.45M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$557.85M+22.0%
Q1 FY2026Mar 31, 2026$465.05M-3.1%
Q4 FY2025Dec 31, 2025$514.16M+4.8%
Q3 FY2025Sep 30, 2025$446.42M-9.1%
Q2 FY2025Jun 30, 2025$457.19M-3.2%
Q1 FY2025Mar 31, 2025$480.05M+2.6%
Q4 FY2024Dec 31, 2024$490.42M-5.1%
Q3 FY2024Sep 30, 2024$491.25M-6.1%
Q2 FY2024Jun 30, 2024$472.42M-10.8%
Q1 FY2024Mar 31, 2024$467.89M-8.2%
Q4 FY2023Dec 31, 2023$516.96M-6.0%
Q3 FY2023Sep 30, 2023$522.92M-6.4%
Q2 FY2023Jun 30, 2023$529.89M+3.8%
Q1 FY2023Mar 31, 2023$509.74M-3.4%
Q4 FY2022Dec 31, 2022$550.00M-6.5%
Q3 FY2022Sep 30, 2022$558.59M+110.2%
Q2 FY2022Jun 30, 2022$510.54M+84.1%
Q1 FY2022Mar 31, 2022$527.72M+85.5%
Q4 FY2021Dec 31, 2021$588.15M+75.7%
Q3 FY2021Sep 30, 2021$265.76M+50.8%
Q2 FY2021Jun 30, 2021$277.28M+29.1%
Q1 FY2021Mar 31, 2021$284.43M+108.2%
Q4 FY2020Dec 31, 2020$334.72M+91.0%
Q3 FY2020Sep 30, 2020$176.23M+94.7%
Q2 FY2020Jun 30, 2020$214.71M+84.5%
Q1 FY2020Mar 31, 2020$136.59M-4.0%
Q4 FY2019Dec 31, 2019$175.28M+19.4%
Q3 FY2019Sep 30, 2019$90.50M-46.2%
Q2 FY2019Jun 30, 2019$116.34M-14.9%
Q1 FY2019Mar 31, 2019$142.34M-8.4%
Q4 FY2018Dec 31, 2018$146.84M-17.6%
Q3 FY2018Sep 30, 2018$168.31M-12.1%
Q2 FY2018Jun 30, 2018$136.64M+20.4%
Q1 FY2018Mar 31, 2018$155.37M+20.0%
Q4 FY2017Dec 31, 2017$178.26M+98.4%
Q3 FY2017Sep 30, 2017$191.49M+109.3%
Q2 FY2017Jun 30, 2017$113.51M–
Q1 FY2017Mar 31, 2017$129.51M–
Q4 FY2016Dec 31, 2016$89.85M–
Q3 FY2016Sep 30, 2016$91.50M–

More BioCryst Pharmaceuticals figures

See a number that looks wrong?